The Impact of Cholecaciferol Supplementation on Bone Mineral Density in Long-Term Kidney Transplant Recipients

• Published in: Biomolecules (Basel, Switzerland) Vol. 13; no. 4; p. 629
• Main Authors: Battaglia, Yuri, Bellasi, Antonio, Esposito, Pasquale, Bortoluzzi, Alessandra, Rotondi, Silverio, Andreucci, Michele, Fiorini, Fulvio, Russo, Domenico, Storari, Alda
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 31-03-2023; MDPI
• Subjects: Adolescent; Biochemistry; Bisphosphonates; Body mass index; Bone Density; Bone diseases; Bone Diseases, Metabolic - drug therapy; Bone Diseases, Metabolic - epidemiology; Bone Diseases, Metabolic - etiology; Bone mineral density; bone mineral disease; Bones; Care and treatment; Cholecalciferol - pharmacology; Cholecalciferol - therapeutic use; Density; Diabetes; Diabetes mellitus; Diphosphonates - therapeutic use; Dosage and administration; Dual energy X-ray absorptiometry; femoral neck; Fractures; Humans; Kidney diseases; Kidney transplantation; Kidney Transplantation - adverse effects; Kidney transplants; Long bone; Morbidity; Nephrology; Organ transplant recipients; Osteopenia; Osteoporosis; Physiological aspects; Population studies; Statistical analysis; Sterols; Supplements; T-score; Vertebrae; Vitamin D; Vitamin D - pharmacology; Vitamin D3; Vitamin deficiency; Z-score; Italy; United States > US; bone mineral disease; lumbar vertebral bodies; T-score; Z-score; DEXA; vitamin D; KDIGO guidelines; kidney transplantation; femoral neck
• ISSN: 2218-273X; 2218-273X
• DOI: 10.3390/biom13040629

Although reduced bone mineral density (BMD) is associated with a higher risk of fractures, morbidity, and mortality in kidney transplant patients (KTRs), there is no consensus on optimal treatment for the alterations of BMD in this population. This study aims at assessing the effect of cholecalciferol supplementation on BMD over a follow-up period of 2 years in a cohort of long-term KTRs. Patients with age ≥ 18 years were included and divided into two subgroups based on treatment with bisphosphonate and/or calcimimetics and/or active vitamin D sterols (KTRs-treated) or never treated with the above medications (KTRs-free). BMD was evaluated at lumbar vertebral bodies (LV) and right femoral neck (FN) with standard DEXA at the beginning and end of the study. According to World Health Organization (WHO) criteria, results were expressed as T-score and Z-score. Osteoporosis and osteopenia were defined as T score ≤ -2.5 SD and T score < -1 and >-2.5 SD, respectively. Cholecalciferol was supplemented at a dose of 25,000 IU/week over 12 weeks followed by 1500 IU/day. KTRs-free (
. 69) and KTRs-treated (
. 49) consecutive outpatients entered the study. KTRs-free were younger (
< 0.05), with a lower prevalence of diabetes (
< 0.05) and of osteopenia at FN (46.3 % vs. 61.2 %) compared to KTRs-treated. At the entry none of the study subjects had a sufficient level of cholecalciferol; Z-score and T-score at LV and FN were not different between groups. At the end of the study period, serum cholecalciferol concentration was significantly increased in both groups (
< 0.001); the KTRs-free group presented an improvement in both T-score and Z-score at LV (
< 0.05) as well as a lower prevalence of osteoporotic cases (21.7% vs. 15.9%); in contrast, no changes were recorded in KTR-treated individuals. In conclusion, supplementation with cholecalciferol ameliorated Z-score and T-score at LV in long-term KTRs who had been never treated with active or inactive vitamin D sterols, bisphosphonates, and calcimimetics. Future endeavours are needed to confirm these preliminary findings.